Grunenthal Gmbh

Gruenenthal Gmbh

Elexopharm Gmbh

Universität Des Saarlandes

Simon Lucas

Gregor Bahrenberg

Achim Kless

Wolfgang Schröder

Sven Kühnert

Stefan Schunk

Florian Jakob

Ingo Konetzki

Paul Ratcliffe

Tobias Craan

Jo Alen

Sebastian Wachten

Simon Cruwys

Rolf Wolfgang Hartmann

Ralf Heim

Sven Kuehnert

Wolfgang Schroeder

Petra Bloms-Funke

The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.

Substituted triazolo quinoxaline derivatives

Further substituted triazolo quinoxaline derivatives

The invention relates to certain compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders that are, at least partially, mediated by TSPO activity.

Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders

The invention relates to specific carboxamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.

Specific carboxamides as KCNQ2/3 modulators

Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted 6-amino-nicotinamides as KCNQ2/3 modulators

The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Heteroquinoline-3-carboxamides as KCNQ2/3 modulators

Substituted 4-aminobenzamides, pharmaceutical compositions containing these compounds and also methods of using these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Substituted 4-aminobenzamides as KCNQ2/3 modulators

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 &#x3b2;-hydroxylase (CYP11 B1). 

6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase CYP11B2

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11&#x3b2;-hydroxylase (CYP11B1) with these compounds.

Growing community of inventors

Aachen, Germany

Simon Lucas